Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
HAIFA, Israel, December 15, 2022 – Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a
leading biotechnology company, announced today that it has signed securities purchase agreements
with domestic and non-U.S. investors for the sale of an aggregate of 7,885,900 of the Company’s
common shares and warrants to purchase up to an aggregate of 7,885,900 of the Company’s common
shares. On December 13, 2022, the Company executed securities purchase agreements to sell, at a
purchase price of $1.03 per share, up to 5,579,883 of the Company’s common shares and warrants to
purchase up to 5,579,883 of the Company’s common shares, with an exercise price of $1.03 per share
and a term of three years. On December 14, 2022, the Company executed securities purchase
agreements to sell, at a purchase price of $1.05 per share, up to 2,068,517 of the Company’s common
shares and warrants to purchase up to 2,068,517 of the Company’s common shares, with an exercise
price of $1.05 per share and a term of three years. On December 15, 2022, the Company executed
securities purchase agreements to sell, at a purchase price of $1.06 per share, up to 237,500 of the
Company’s common shares and warrants to purchase up to 237,500 of the Company’s common shares,
with an exercise price of $1.06 per share and a term of three years. The warrants sold in the offerings
will be exercisable upon the later of six months from their issuance date, or until the Company increases
its authorized shares. In addition, Yaky Yanay, the Company’s Chief Executive Officer, has committed to
forgo $375,000 of his annual cash salary for the next twelve months in return for equity grants issuable
under the Company’s existing equity compensation plans. The offerings are expected to close by January
31, 2023.
The offerings are being made in the United States pursuant to the exemption from securities
registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of
Regulation D as promulgated by the Securities and Exchange Commission (the "SEC"). The securities
have not been registered under the Securities Act of 1933, as amended, or applicable state securities
laws, and accordingly may not be offered or sold in the United States absent registration with the SEC or
an applicable exemption from such registration requirements.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there
be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction.
